About this episode
In our What's Trending in Aesthetics episodes we discuss the topics doing the rounds on social media, the issues being debated in injector forums and the stories making the news: the controversies and themes that have the industry talking.
In Chapter 19, Dr Jake Sloane and David Segal cover five topics: the growing influence of private equity and what Obagi Medical's sale could mean for clinics; Allergan's 'Undetectable Era' and the evolving definition of natural-looking results; patient education and clinical photography; counterfeit toxin concerns following an FDA warning letter; and AI-accelerated longevity research and what it could mean for aesthetics.
What you'll learn
- Private equity in aesthetics, and what Obagi Medical's sale could mean for clinics
- Allergan's 'Undetectable Era' and how natural results are being redefined
- Patient education basics, biostimulators vs fillers, and consultation photos
- Counterfeit toxin risks after an FDA warning letter, and how patients can verify safety
- AI-accelerated longevity research, and what it could mean for aesthetics
Topics
- What's Trending in Aesthetics
- Private equity
- Obagi
- Allergan
- Natural results
- Counterfeit toxins
- FDA
- Longevity
- AI in healthcare
Full transcript
The full transcript for this episode is coming soon.